Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Céline Vidaillac

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmacotherapy|April 29, 2009
Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureusCéline Vidaillac, Michael J Rybak
Antimicrobial Agents and Chemotherapy|July 4, 2012
In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolatesCéline Vidaillac, Lothaire Benichou, Raphaël E Duval
International Journal of Antimicrobial Agents|March 30, 2010
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolatesCéline Vidaillac, Steve N Leonard, Michael J Rybak
Antimicrobial Agents and Chemotherapy|November 30, 2011
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Céline Vidaillac, Michael J Rybak
The Journal of Antibiotics|October 14, 2010
A new assay to determine oritavancin concentrationsCéline Vidaillac, Jeffrey R Aeschlimann, Michael J Rybak
Antimicrobial Agents and Chemotherapy|May 6, 2009
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetationsSteven N Leonard, Céline Vidaillac, Michael J Rybak
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 11, 2012
Macrolides and staphylococcal biofilmsJorge Parra-Ruiz, Céline Vidaillac, Michael J Rybak
Diagnostic Microbiology and Infectious Disease|October 25, 2011
In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycinCéline Vidaillac, Jorge Parra-Ruiz, Michael Joseph Rybak
Antimicrobial Agents and Chemotherapy|September 10, 2009
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber modelCéline Vidaillac, Steve N Leonard, Michael J Rybak
Antimicrobial Agents and Chemotherapy|February 23, 2012
Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Céline Vidaillac, Patricia Winterfield, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmacotherapy|April 29, 2009
Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureusCéline Vidaillac, Michael J Rybak
Antimicrobial Agents and Chemotherapy|July 4, 2012
In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolatesCéline Vidaillac, Lothaire Benichou, Raphaël E Duval
International Journal of Antimicrobial Agents|March 30, 2010
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolatesCéline Vidaillac, Steve N Leonard, Michael J Rybak
Antimicrobial Agents and Chemotherapy|November 30, 2011
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Céline Vidaillac, Michael J Rybak
The Journal of Antibiotics|October 14, 2010
A new assay to determine oritavancin concentrationsCéline Vidaillac, Jeffrey R Aeschlimann, Michael J Rybak
Antimicrobial Agents and Chemotherapy|May 6, 2009
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetationsSteven N Leonard, Céline Vidaillac, Michael J Rybak
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 11, 2012
Macrolides and staphylococcal biofilmsJorge Parra-Ruiz, Céline Vidaillac, Michael J Rybak
Diagnostic Microbiology and Infectious Disease|October 25, 2011
In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycinCéline Vidaillac, Jorge Parra-Ruiz, Michael Joseph Rybak
Antimicrobial Agents and Chemotherapy|September 10, 2009
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber modelCéline Vidaillac, Steve N Leonard, Michael J Rybak
Antimicrobial Agents and Chemotherapy|February 23, 2012
Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Céline Vidaillac, Patricia Winterfield, et al.
Pageof 2